SOHO 2023 | Addressing under-representation of elderly patients in DLBCL clinical trials
Pallawi Torka, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the issue of under-representation of elderly patients with diffuse large B-cell lymphoma (DLBCL) in clinical trials, and the need to design trials for fit, unfit, or frail elderly patients. Dr Torka comments on unsuccessful studies, such as PHOENIX (NCT01855750), to highlight the requirement for patient randomization based on geriatric assessment. The challenges associated with trials specific to frail, elderly patients are also mentioned, with reference to the Phase III SENIOR study (NCT02128061). This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy fees from Genentech, Genmab, Seagen, ADC therapeutics, TG therapeutics, Lilly USA.
